| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | JTK8; p53Lyn; p56Lyn |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human LYN |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于LYN抗体的模拟参考文献示例(内容基于公开研究领域知识概括，非真实文献)：
---
1. **文献名称**：*LYN Kinase in B-cell Receptor Signaling: Mechanisms and Therapeutic Implications*
**作者**：Smith A, et al.
**摘要**：研究探讨了LYN激酶在B细胞受体(BCR)信号传导中的双重作用，既作为激活剂又通过负反馈调节抑制过度免疫反应。文章指出LYN抗体可用于阻断异常BCR信号，或作为慢性淋巴细胞白血病(CLL)的潜在治疗靶点。
2. **文献名称**：*Aberrant LYN Activation Promotes Drug Resistance in Acute Myeloid Leukemia*
**作者**：Chen L, et al.
**摘要**：该研究发现LYN在急性髓系白血病(AML)中异常激活，与化疗耐药性相关。通过LYN特异性抗体抑制其活性，可增强传统化疗药物对AML细胞的杀伤效果，提示LYN抗体在联合治疗中的应用价值。
3. **文献名称**：*LYN as a Regulator of Autoimmune Responses: Insights from Lupus Models*
**作者**：Rodríguez P, et al.
**摘要**：研究利用系统性红斑狼疮(SLE)小鼠模型，发现LYN表达水平降低会导致B细胞过度活化并加剧自身免疫反应。使用LYN激动型抗体可部分恢复免疫稳态，为自身免疫疾病的抗体疗法提供了新思路。
---
如需实际文献，建议通过PubMed或Google Scholar检索关键词“LYN kinase antibody”、“LYN therapeutic target”等，并筛选近年高影响力论文。
The LYN antibody targets LYN, a non-receptor tyrosine kinase belonging to the SRC family. Primarily expressed in hematopoietic cells, particularly B cells and myeloid cells, LYN plays dual roles in intracellular signaling. It regulates key pathways, including B-cell receptor (BCR) signaling, cytokine receptor activation, and integrin-mediated responses. LYN activates downstream effectors like SYK and PI3K but also exerts inhibitory effects by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on receptors such as CD22 and FcγRIIB. This duality contributes to its involvement in both pro-survival and anti-proliferative signals.
Dysregulated LYN activity is implicated in hematologic malignancies (e.g., chronic lymphocytic leukemia, acute myeloid leukemia) and autoimmune disorders (e.g., systemic lupus erythematosus). Overexpression or mutations in LYN can lead to constitutive signaling, promoting cell survival and resistance to apoptosis. Conversely, loss of LYN function may disrupt immune tolerance.
LYN antibodies are essential tools for studying its expression, phosphorylation status, and interactions in disease models. They aid in elucidating LYN's role in oncogenesis and immune dysregulation, as well as evaluating therapeutic strategies targeting LYN, such as small-molecule inhibitors (e.g., dasatinib) or monoclonal antibodies in preclinical and clinical development. Research continues to explore LYN's context-dependent signaling mechanisms and its potential as a biomarker or therapeutic target.
×
